Pharmacokinetic drug interactions between antiseizure medications and drugs for comorbid diseases in children with epilepsy.

INTRODUCTION : Nearly 80% of children with epilepsy have one or more chronic comorbidity that requires specific drug treatments in several cases. Drug-drug interactions (DDIs) between antiseizure medications (ASMs) and all other drugs (NON-ASMs) used to treat comorbid diseases may have serious consequences. AREAS COVERED : All potential DDIs between 27 ASMs and all NON-ASMs used as oral chronic treatment of those disorders most often comorbid with epilepsy in children were searched in drug compendia. Clinical evidence of the identified DDIs was also searched in the literature. Forty-eight drugs have been identified with potential DDIs with at least one ASM. Most important DDIs are between some ASMs and omeprazole and pantoprazole (drugs for gastrointestinal disorders), ibuprofen and cyclobenzaprine (drugs for musculoskeletal disorders), loratidine, lumacaftor/ivacaftor, montelukast, and theophylline (drugs for respiratory system), levothyroxine, liothyronine and several corticosteroids (systemic hormonal preparations), almotriptan, dihydroergotamine, ergotamine, and several antipsychotics, antidepressants and anxiolytics (drugs for nervous diseases). Clinical evidence of the predicted DDIs was found in a minority of cases. EXPERT OPINION : Treatment of children with epilepsy should be decided considering treatment of both seizures and comorbid diseases and aimed at minimizing the risk of DDIs between ASMs and NON-ASMs.